Form 4: Vera Therapeutics SVP, Finance, Chief Accounting Officer Reports Sale of Class A Common Stock

Joseph R. Young, SVP, Finance, Chief Accounting Officer of Vera Therapeutics, sold 5,714 shares of Class A Common Stock at $40 per share on April 10, 2024.

Summary

• On April 10, 2024, Joseph R. Young, the SVP, Finance, and Chief Accounting Officer of Vera Therapeutics, sold 5,714 shares of Class A Common Stock.
• The sale price was $40 per share.
• Following the transaction, Young directly owns 53,171 shares of Class A Common Stock.
• This includes 1,831 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2024.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of an insider stock sale. The sentiment is neither particularly positive nor negative as it simply reflects a transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions, allowing investors to see if those with inside knowledge of the company are buying or selling shares.

Stakeholder Impact

• The sale of shares by a company officer may be perceived differently by stakeholders.
• Some may view it as a lack of confidence in the company's future, while others may see it as a personal financial decision.

Key Dates